BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT)

PHARMACEUTICAL PREPARATIONS

Headquarters
United States
Employees
106
Market Cap
$681M

About BridgeBio Oncology Therapeutics, Inc. Common Stock

BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.

SentiSense also tracks daily options readings for BridgeBio Oncology Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.

BridgeBio Oncology Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.